Literature DB >> 21080112

Treatment of chronic migraine.

Hans-Christoph Diener1, Dagny Holle, David Dodick.   

Abstract

Chronic migraine is defined in different ways. The most commonly used definition is headache on more than 15 days per month in patients with migraine. Chronic migraine is difficult to treat and requires a multidisciplinary approach. Only two pharmacological treatments have been shown to be effective in placebo-controlled randomized trials: topiramate and local injection of botulinum toxin. Both therapies are effective in patients with chronic migraine with and without medication overuse. Many other substances have been investigated in chronic daily headache. All trials were underpowered and, therefore, recommendations concerning possible efficacy are not possible.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21080112     DOI： 10.1007/s11916-010-0159-x

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN： 1534-3081


  39 in total

1.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

Review 2.  Risk factors for headache chronification.

Authors:  Ann I Scher; Lynn A Midgette; Richard B Lipton
Journal:  Headache       Date:  2008-01       Impact factor: 5.887

3.  New appendix criteria open for a broader concept of chronic migraine.

Authors:  J Olesen; M-G Bousser; H-C Diener; D Dodick; M First; P J Goadsby; H Göbel; M J A Lainez; J W Lance; R B Lipton; G Nappi; F Sakai; J Schoenen; S D Silberstein; T J Steiner
Journal:  Cephalalgia       Date:  2006-06       Impact factor: 6.292

4.  Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen D Silberstein; Richard B Lipton; David W Dodick; Frederick G Freitag; Nabih Ramadan; Ninan Mathew; Jan L Brandes; Marcelo Bigal; Joel Saper; Steven Ascher; Donna M Jordan; Steven J Greenberg; Joseph Hulihan
Journal:  Headache       Date:  2007-02       Impact factor: 5.887

5.  Topiramate in the treatment of chronic migraine.

Authors:  M Silvestrini; M Bartolini; M Coccia; R Baruffaldi; R Taffi; L Provinciali
Journal:  Cephalalgia       Date:  2003-10       Impact factor: 6.292

6.  Chronic daily headache prophylaxis with tizanidine: a double-blind, placebo-controlled, multicenter outcome study.

Authors:  Joel R Saper; Alvin E Lake; Deborah T Cantrell; Paul K Winner; Jeffery R White
Journal:  Headache       Date:  2002-06       Impact factor: 5.887

Review 7.  Overuse of acute migraine medications and migraine chronification.

Authors:  Marcelo E Bigal; Richard B Lipton
Journal:  Curr Pain Headache Rep       Date:  2009-08

8.  Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment.

Authors:  Marcelo E Bigal; Daniel Serrano; Michael Reed; Richard B Lipton
Journal:  Neurology       Date:  2008-08-19       Impact factor: 9.910

9.  Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.

Authors:  Sheena K Aurora; Marek Gawel; Jan L Brandes; Suriani Pokta; Amanda M Vandenburgh
Journal:  Headache       Date:  2007-04       Impact factor: 5.887

10.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292
View more
  14 in total

Review 1.  Rationale for use of onabotulinum toxin A (BOTOX) in chronic migraine.

Authors:  P Barbanti; G Egeo; L Fofi; C Aurilia; S Piroso
Journal:  Neurol Sci       Date:  2015-05       Impact factor: 3.307

Review 2.  A Narrative Review of Evidence-Based Preventive Options for Chronic Migraine.

Authors:  Amaal J Starling; Bert B Vargas
Journal:  Curr Pain Headache Rep       Date:  2015-10

Review 3.  Behavioral therapy for chronic migraine.

Authors:  Francesca Pistoia; Simona Sacco; Antonio Carolei
Journal:  Curr Pain Headache Rep       Date:  2013-01

Review 4.  Neurovascular contributions to migraine: Moving beyond vasodilation.

Authors:  Blaine Jacobs; Gregory Dussor
Journal:  Neuroscience       Date:  2016-06-14       Impact factor: 3.590

Review 5.  Treatment of Chronic Migraine with Focus on Botulinum Neurotoxins.

Authors:  Sara M Schaefer; Christopher H Gottschalk; Bahman Jabbari
Journal:  Toxins (Basel)       Date:  2015-07-14       Impact factor: 4.546

6.  Prevalence of chronic headache in Croatia.

Authors:  Vlasta Vuković-Cvetković; Davor Plavec; Arijana Lovrenčić-Huzjan
Journal:  Biomed Res Int       Date:  2013-09-01       Impact factor: 3.411

7.  The role of headache chronicity among predictors contributing to quality of life in patients with migraine: a hospital-based study.

Authors:  Sun-Young Kim; Sung-Pa Park
Journal:  J Headache Pain       Date:  2014-10-02       Impact factor: 7.277

Review 8.  Targeting TRP channels for novel migraine therapeutics.

Authors:  Gregory Dussor; J Yan; Jennifer Y Xie; Michael H Ossipov; David W Dodick; Frank Porreca
Journal:  ACS Chem Neurosci       Date:  2014-08-29       Impact factor: 4.418

9.  Atenolol in the prophylaxis of chronic migraine: a 3-month open-label study.

Authors:  Bengt Edvardsson
Journal:  Springerplus       Date:  2013-09-22

10.  Two-component signal transduction system CBO0787/CBO0786 represses transcription from botulinum neurotoxin promoters in Clostridium botulinum ATCC 3502.

Authors:  Zhen Zhang; Hannu Korkeala; Elias Dahlsten; Elina Sahala; John T Heap; Nigel P Minton; Miia Lindström
Journal:  PLoS Pathog       Date:  2013-03-28       Impact factor: 6.823
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.